Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

Completed · Phase 2

Conditions studied: Lymphoma, Follicular

In brief

To investigate the efficacy in two dose regimens of ofatumumab in combination with CHOP (cyclophosphamide,doxorubicin, vincristine,prednisolone) in previously untreated patients with Follicular Lymphoma (FL)

Key facts

Study ID

NCT00494780

Run by

GlaxoSmithKline

People needed

59

Starts

2007-06-01

Expected to finish

2010-09-01

Last updated by the study team

2014-07-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient with Follicular Lymphoma (FL)
• Confirmed diagnosis of Follicular lymphoma
• 18 years or above
• Verbal and written information about the study

You may not qualify if…

• No previous treatment for Follicular Lymphoma
• Clinical suspicion that the Follicular Lymphoma has transformed to aggressive lymphoma
• Several diseases such as malignancies etc.
• Screening laboratory values
• Current participation in any other interventional clinical study
• Breast feeding women or pregnant women
• Women of childbearing potential not willing to use adequate contraception

Where it is running

• GSK Investigational Site — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.